Literature DB >> 11071656

Extensive genetic alterations of the HLA region, including homozygous deletions of HLA class II genes in B-cell lymphomas arising in immune-privileged sites.

S A Riemersma1, E S Jordanova, R F Schop, K Philippo, L H Looijenga, E Schuuring, P M Kluin.   

Abstract

In B-cell lymphomas, loss of human leukocyte antigen (HLA) class I and II molecules might contribute to immune escape from CD8(+) and CD4(+) cytotoxic T cells, especially because B cells can present their own idiotype. Loss of HLA expression and the possible underlying genomic alterations were studied in 28 testicular, 11 central nervous system, and 21 nodal diffuse large B-cell lymphomas (DLCLs), the first two sites are considered as immune-privileged sites. The analysis included immunohistochemistry, loss of heterozygosity analysis, and fluorescent in situ hybridization (FISH) on interphase cells and isolated DNA fibers. Total loss of HLA-A expression was found in 60% of the extranodal cases and in 10% of the nodal cases (P <.01), whereas loss of HLA-DR expression was found in 56% and 5%, respectively (P <.01). This was accompanied by extensive loss of heterozygosity within the HLA region in the extranodal DLCLs. In 3 cases, retention of heterozygosity for D6S1666 in the class II region suggested a homozygous deletion. This finding was confirmed by interphase FISH that showed homozygous deletions in the class II genes in 11 of the 18 extranodal lymphomas but in none of the 7 nodal DLCLs (P <.001). Mapping by fiber FISH showed variable deletions that always included HLA-DQ and HLA-DR genes. Hemizygous deletions and mitotic recombinations often involving all HLA genes were found in 13 of 18 extranodal and 2 of 7 nodal lymphomas. In conclusion, a structural loss of HLA class I and II expression might help the B-cell lymphoma cells to escape from immune attack.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11071656

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  59 in total

1.  Partial plasma cell differentiation as a mechanism of lost major histocompatibility complex class II expression in diffuse large B-cell lymphoma.

Authors:  Sarah T Wilkinson; Kristie A Vanpatten; Diane R Fernandez; Patrick Brunhoeber; Karl E Garsha; Betty J Glinsmann-Gibson; Thomas M Grogan; Julie Teruya-Feldstein; Lisa M Rimsza
Journal:  Blood       Date:  2011-12-13       Impact factor: 22.113

2.  Combined genetic inactivation of β2-Microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma.

Authors:  Madhavi Challa-Malladi; Yen K Lieu; Olivia Califano; Antony B Holmes; Govind Bhagat; Vundavalli V Murty; David Dominguez-Sola; Laura Pasqualucci; Riccardo Dalla-Favera
Journal:  Cancer Cell       Date:  2011-12-01       Impact factor: 31.743

3.  Loss of major histocompatibility class II expression in non-immune-privileged site diffuse large B-cell lymphoma is highly coordinated and not due to chromosomal deletions.

Authors:  Lisa M Rimsza; Robin A Roberts; Elias Campo; Thomas M Grogan; Silvia Bea; Itziar Salaverria; Andreas Zettl; Andreas Rosenwald; German Ott; H Konrad Muller-Hermelink; Jan Delabie; Richard I Fisher; Joseph M Unger; Michael Leblanc; Louis M Staudt; Elaine S Jaffe; Randy D Gascoyne; Wing C Chan; Dennis D Weisenburger; Timothy Greiner; Rita M Braziel; Thomas P Miller
Journal:  Blood       Date:  2005-10-20       Impact factor: 22.113

Review 4.  Ontogeny, Genetics, Molecular Biology, and Classification of B- and T-Cell Non-Hodgkin Lymphoma.

Authors:  Russell James Hubbard Ryan; Ryan Alan Wilcox
Journal:  Hematol Oncol Clin North Am       Date:  2019-05-18       Impact factor: 3.722

5.  Loss of major histocompatibility class II gene and protein expression in primary mediastinal large B-cell lymphoma is highly coordinated and related to poor patient survival.

Authors:  Robin A Roberts; George Wright; Andreas R Rosenwald; Marina A Jaramillo; Thomas M Grogan; Thomas P Miller; Yvette Frutiger; Wing C Chan; Randy D Gascoyne; German Ott; H Konrad Muller-Hermelink; Louis M Staudt; Lisa M Rimsza
Journal:  Blood       Date:  2006-03-16       Impact factor: 22.113

6.  Loss of HLA-DR expression and immunoblastic morphology predict adverse outcome in diffuse large B-cell lymphoma - analyses of cases from two prospective randomized clinical trials.

Authors:  Heinz-Wolfram Bernd; Marita Ziepert; Christoph Thorns; Wolfram Klapper; Hans-Heinrich Wacker; Michael Hummel; Harald Stein; Martin-Leo Hansmann; German Ott; Andreas Rosenwald; Hans-Konrad Müller-Hermelink; Thomas F E Barth; Peter Möller; Sergio B Cogliatti; Michael Pfreundschuh; Norbert Schmitz; Lorenz Trümper; Silvia Höller; Markus Löffler; Alfred C Feller
Journal:  Haematologica       Date:  2009-11       Impact factor: 9.941

7.  Low levels of monoclonal small B cells in the bone marrow of patients with diffuse large B-cell lymphoma of activated B-cell type but not of germinal center B-cell type.

Authors:  Anne M Tierens; Harald Holte; Abdirashid Warsame; Ida M Ikonomou; Junbai Wang; Wing C Chan; Jan Delabie
Journal:  Haematologica       Date:  2010-02-09       Impact factor: 9.941

8.  Coordinate loss of MHC class II expression in the diffuse large B cell lymphoma cell line OCI-Ly2 is due to a novel mutation in RFX-AP.

Authors:  Meghan Bushway; Kelly A Cycon; Kathleen Mulvaney; Shawn P Murphy
Journal:  Immunogenetics       Date:  2009-12-19       Impact factor: 2.846

9.  Microarray analysis of B-cell lymphoma cell lines with the t(14;18).

Authors:  Ryan S Robetorye; Sandra D Bohling; John W Morgan; G Chris Fillmore; Megan S Lim; Kojo S J Elenitoba-Johnson
Journal:  J Mol Diagn       Date:  2002-08       Impact factor: 5.568

10.  EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity.

Authors:  M K Gandhi; T Hoang; S C Law; S Brosda; K O'Rourke; J W D Tobin; F Vari; V Murigneux; L Fink; J Gunawardana; C Gould; H Oey; K Bednarska; S Delecluse; R U Trappe; L Merida de Long; M B Sabdia; G Bhagat; G Hapgood; E Blyth; L Clancy; J Wight; E Hawkes; L M Rimsza; A Maguire; K Bojarczuk; B Chapuy; C Keane
Journal:  Blood       Date:  2021-03-18       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.